-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, IBFhAYv0sMrePfOA98PCUw11CfipvoUilTgToEG7hIdJjd7j/0Q2zmzCy/xazfHB 8IDJKrDoJpo+fQb5rHst3Q== 0000950148-96-000421.txt : 19960326 0000950148-96-000421.hdr.sgml : 19960326 ACCESSION NUMBER: 0000950148-96-000421 CONFORMED SUBMISSION TYPE: DEF 14A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 19960328 FILED AS OF DATE: 19960325 SROS: NYSE FILER: COMPANY DATA: COMPANY CONFORMED NAME: DIAGNOSTIC PRODUCTS CORP CENTRAL INDEX KEY: 0000702259 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 952802182 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: DEF 14A SEC ACT: 1934 Act SEC FILE NUMBER: 001-09957 FILM NUMBER: 96537954 BUSINESS ADDRESS: STREET 1: 5700 W 96TH ST CITY: LOS ANGELES STATE: CA ZIP: 90045 BUSINESS PHONE: 2137760180 DEF 14A 1 DEFINITIVE PROXY MATERIALS 1 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant /X/ Filed by a Party other than the Registrant / / Check the appropriate box: / / Preliminary Proxy Statement / / Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) /X/ Definitive Proxy Statement / / Definitive Additional Materials / / Soliciting Material Pursuant to sec.240.14a-11(c) or sec.240.14a-12
DIAGNOSTIC PRODUCTS CORPORATION - -------------------------------------------------------------------------------- (Name of Registrant as Specified In Its Charter) DIAGNOSTIC PRODUCTS CORPORATION - -------------------------------------------------------------------------------- (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): /X/ $125 per Exchange Act Rules 0-11(c)(1)(ii), or 14a-6(i)(1), or 14a-6(i)(2) or Item 22(a)(2) of Schedule 14A. / / $500 per each party to the controversy pursuant to Exchange Act Rule 14a-6(i)(3). / / Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11. (1) Title of each class of securities to which transaction applies: ---------------------------------------------------------------------- (2) Aggregate number of securities to which transaction applies: ---------------------------------------------------------------------- (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was determined): ---------------------------------------------------------------------- (4) Proposed maximum aggregate value of transaction: ---------------------------------------------------------------------- (5) Total fee paid: ---------------------------------------------------------------------- / / Fee paid previously with preliminary materials. / / Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. (1) Amount Previously Paid: ---------------------------------------------------------------------- (2) Form, Schedule or Registration Statement No.: ---------------------------------------------------------------------- (3) Filing Party: ---------------------------------------------------------------------- (4) Date Filed: ---------------------------------------------------------------------- 2 [LOGO] DIAGNOSTIC PRODUCTS CORPORATION 5700 WEST 96TH STREET LOS ANGELES, CA 90045 NOTICE OF ANNUAL MEETING OF SHAREHOLDERS TO BE HELD MAY 8, 1996 TO THE SHAREHOLDERS: NOTICE IS HEREBY GIVEN that the Annual Meeting of Shareholders of Diagnostic Products Corporation will be held at the Company's offices at 5700 West 96th Street, Los Angeles, California, on May 8, 1996, at 2:30 p.m. local time, for the following purposes: 1. To elect a Board of Directors to serve until the next Annual Meeting of Shareholders and until their respective successors are elected and qualified. The nominees for election to the Board of Directors are: Dr. Sigi Ziering, Sidney A. Aroesty, Marilyn Ziering, Maxwell H. Salter, Dr. James D. Watson, Michael Ziering and Frederick Frank. 2. To transact such other business and to consider and take action upon any and all matters that may properly come before the Meeting or any adjournment thereof. The Board of Directors has fixed the close of business, March 15, 1996, as the record date for the determination of the shareholders entitled to notice of and to vote at the Meeting. SHAREHOLDERS WHO ARE UNABLE TO ATTEND THE MEETING PERSONALLY ARE REQUESTED BY MANAGEMENT TO MARK, SIGN AND RETURN THE ENCLOSED PROXY IMMEDIATELY. By Order of the Board of Directors MARILYN ZIERING Secretary March 28, 1996 3 [LOGO] DIAGNOSTICS PRODUCTS CORPORATION PROXY STATEMENT FOR ANNUAL MEETING OF SHAREHOLDERS MAY 8, 1996 The enclosed proxy is solicited by and on behalf of the Board of Directors of Diagnostic Products Corporation (the "Company") in connection with the Annual Meeting of Shareholders to be held at the Company's executive offices located at 5700 West 96th Street, Los Angeles, California, on May 8, 1996, at 2:30 p.m. local time, and any adjournments thereof. It is expected that this Proxy Statement and accompanying proxy will first be mailed to shareholders on or about March 28, 1996. The expenses for soliciting proxies for the Annual Meeting are to be paid by the Company. Solicitation of proxies may be made by means of personal calls upon, or telephonic or telegraphic communications with, shareholders or their personal representatives by directors, officers and employees of the Company who will not be specially compensated for such services. VOTING PROCEDURES Only shareholders of record of the Company's Common Stock at the close of business on March 15, 1996, the record date fixed by the Board of Directors, are entitled to notice of and to vote at the Meeting. On that date, there were outstanding and entitled to vote at the Meeting, 13,533,156 shares of Common Stock, each of which is entitled to one vote. A majority of the shares entitled to vote, represented in person or by proxy, constitutes a quorum at the Meeting. Abstentions and broker non-votes are counted as present for purposes of determining the existence of a quorum. All shares represented by the accompanying proxy, if the proxy is properly executed and returned, will be voted as specified by the shareholder or, if no vote is indicated, the proxy will be voted FOR the nominees for director. As to any other matter of business which may properly be brought before the Meeting, a vote may be cast pursuant to the accompanying proxy in accordance with the judgment and discretion of the person or persons voting the same, although management does not presently know of any such other matter of business. A shareholder has the power to revoke his proxy at any time before it has been voted by notifying the Company in writing, by submitting a substitute proxy having a later date or by voting in person at the Meeting. If, prior to the election of directors, any shareholder has given notice that he intends to cumulate his votes, then, for the election of directors only, each shareholder may cumulate votes for any nominee, if the nominee's name was placed in nomination prior to the voting. In cumulative voting, each shareholder is entitled in the election of directors to one vote for each voting share held by him multiplied by the number of directors to be elected and may cast all such votes for a single nominee for director or may distribute them among any two or more nominees as he sees fit. See "Election of Directors." 1 4 ELECTION OF DIRECTORS The shareholders are being asked to elect seven directors to serve until the next Annual Meeting of Shareholders and until their successors are duly elected and qualified. The proxies will be voted in favor of the nominees, all of whom are currently serving as directors, unless otherwise specifically instructed. Although the Board of Directors does not anticipate that any nominee will be unavailable for election, in the event of such occurrence the proxies will be voted for such substitute, if any, as the Board of Directors may designate. The seven nominees receiving the highest number of affirmative votes of the shares entitled to be voted will be elected directors; votes withheld and broker non-votes have no legal effect. If voting for directors is conducted by cumulative voting, the persons named on the enclosed proxy will have discretionary authority to distribute votes among the nominees in such proportions as they may see fit, unless otherwise specifically instructed. In any case, the proxies may be voted for less than the entire number of nominees if any situation arises which, in the opinion of the proxy holders, makes such action necessary or desirable. The following information is supplied with respect to the nominees:
PRINCIPAL DIRECTOR NAME AGE OCCUPATION SINCE - ------------------------ --- ------------------------------------------ -------- Sigi Ziering, Ph.D. 68 Chairman of the Board, 1973 Chief Executive Officer Sidney A. Aroesty 49 Consultant 1981 Marilyn Ziering 64 Vice President -- Marketing Communications 1974 Maxwell H. Salter 76 Chairman of the Board and Chief 1982 Executive Officer, Benos James D. Watson, Ph.D. 67 President, Cold Spring Harbor Laboratory 1987 Michael Ziering 39 President and Chief Operating Officer 1994 Frederick Frank 63 Vice Chairman, Lehman Brothers Inc. 1996
Sigi Ziering and Marilyn Ziering are husband and wife. Michael Ziering is the son of Dr. and Mrs. Ziering. See "Ownership of Common Stock" for information concerning the beneficial ownership of the Company's Common Stock by nominees for director. Dr. Sigi Ziering joined the Company as treasurer and director in 1973 and has served as Chief Executive Officer since 1974. Dr. Ziering holds a Ph.D. in Theoretical Physics from Syracuse University. Mr. Aroesty joined the Company in 1978. He served as Executive Vice President and Chief Operating Officer from 1982 through 1988 and as President and Chief Operating Officer from 1989 to September 1994. He currently serves as a consultant to the Company. Mr. Aroesty holds a B.S. degree in biochemistry from the University of Rochester. Mrs. Ziering joined the Company in 1973 as Secretary and served as Vice President -- Marketing from 1979 until February 1993 when she was elected Vice President -- Marketing Communications. Mrs. Ziering holds a Masters Degree from Syracuse University. Mr. Salter is Chairman of the Board and Chief Executive Officer of Benos, a chain of family clothing stores in which Mr. Salter has been a principal since 1946. 2 5 Dr. Watson was the Director of Cold Spring Harbor Laboratory of New York, a biotechnology research center, from 1968 until he became President in January 1994. Dr. Watson received the Nobel prize in 1962 for his discovery of the double helix structure of the DNA molecule. Dr. Watson is also a director of Pall Corporation. Mr. Michael Ziering, an attorney, joined the Company in 1986 as legal counsel. He served as Vice President-Administration from December 1988 until his election as President and Chief Operating Officer in September 1994. Mr. Frank, who was elected a director of the Company on January 25, 1996, is Vice Chairman of Lehman Brothers Inc., an investment banking firm which he joined as a partner in October 1969. He is a Chartered Financial Analyst, a member of The New York Society of Security Analysts and a past president of the Chemical Processing Industry Analysts. Mr. Frank serves as a director of Applied Bioscience International Inc., Automated Call Processing, Digital Collections, Inc., Physician Computer Network and R.P. Scherer Corporation. He is Chairman of the National Genetics Foundation, a Member of the Salk Institute National Council, a Director of the Salk Institute, a Trustee of the Hotchkiss School, a Member of the Yale School of Organization and Management Advisory Board, and a Member of the Board of Governors of the National Center for Genome Resources. MEETINGS OF THE BOARD OF DIRECTORS AND ITS COMMITTEES The Board of Directors held five meetings in 1995. The Board of Directors has appointed an Executive Committee consisting of Sigi Ziering, Marilyn Ziering and Maxwell H. Salter. The Executive Committee may exercise the full authority of the Board, subject to certain statutory limitations. The Audit Committee, currently comprised of Frederick Frank and Maxwell H. Salter, is responsible for periodically reviewing the financial condition and the results of audit examinations of the Company with its independent public accountants. The Audit Committee met twice during 1995. The Compensation Committee, currently comprised of Frederick Frank, Maxwell Salter and Louis Colen (a shareholder of the Company), is responsible for reviewing and recommending the approval to the Board of Directors of compensation of the officers of the Company. The Compensation Committee met once during 1995. Mr. Frank was appointed to the Compensation Committee in February 1996 and did not take part in the consideration of executive compensation for 1995 as discussed in the Report of the Compensation and Stock Option Committees appearing elsewhere in this Proxy Statement. The Stock Option Committee, comprised of Maxwell H. Salter and Marilyn Ziering, is responsible for administering the Company's Stock Option Plans and approving option grants. The Stock Option Committee took action by written consent on numerous occasions in 1995. The Board of Directors has not designated a nominating committee. COMPENSATION OF DIRECTORS Non-employee directors of the Company receive $1,000 per month as a director's fee. Non-employee directors are also reimbursed their out-of-pocket expenses for attending Board and Committee meetings. Messrs. Aroesty and Watson provide consulting services to the Company for which they were paid $84,000 and $12,000, respectively, in 1995. Mr. Aroesty consults with respect to manufacturing, international marketing, strategic planning and customer relations, and Dr. Watson consults with respect to technology, research and product development. 3 6 EXECUTIVE OFFICERS The executive officers of the Company are as follows:
NAME AGE POSITION - ----------------------- --- ---------------------------------------------- Sigi Ziering, Ph.D. 68 Chairman of the Board and Chief Executive Officer Michael Ziering 39 President and Chief Operating Officer Said El Shami 53 Senior Vice President -- Research and Development and Chief Scientific Officer Marilyn Ziering 64 Vice President -- Marketing Communications and Secretary Julian R. Bockserman 59 Vice President -- Finance Kathy J. Maugh 51 Vice President -- Operations John G. McLaughlin 47 Vice President -- Sales and Marketing
For information concerning the business experience of Sigi Ziering, Michael Ziering and Marilyn Ziering, see "Election of Directors." Mr. El Shami joined the Company in 1978 as Assistant Director of Research, was elected Director of Research in 1980 and was elected Vice President -- Research in 1982. Mr. El Shami was elected Senior Vice President -- Research and Development in 1992 and Chief Scientific Officer in December 1995. Mr. Bockserman, a Certified Public Accountant, joined the Company in 1982 as Controller, was elected Chief Financial Officer in 1982 and was elected Vice President -- Finance in 1983. Ms. Maugh joined the Company in 1986 as a Product Manager. In 1988 she became a Technical Manager for the Company's product support group. She was promoted to Director of Product Support in 1990 and elected Vice President -- Operations in May 1992. Mr. McLaughlin joined the Company in February 1993 as Vice President -- Sales and Marketing. From May 1992 until joining the Company, Mr. McLaughlin served as an independent marketing consultant to diagnostic companies, and he provided consulting services to the Company beginning in December 1992. Mr. McLaughlin was President of Biometric Imaging, a biotechnology start-up company developing high-sensitivity instrument systems, from September 1991 until May 1992. He served as Vice President, Marketing with Unipath Company, a manufacturer of hematology instruments and immunodiagnostics, from March 1989 through September 1991. Officers of the Company serve at the discretion of the Board of Directors. 4 7 EXECUTIVE COMPENSATION SUMMARY COMPENSATION TABLE The following table provides compensation information with respect to the Chief Executive Officer and the four other most highly paid persons who were executive officers at December 31, 1995 (the "Named Officers") for services in all capacities during fiscal years 1995, 1994 and 1993.
LONG-TERM COMPENSATION ANNUAL --------------- COMPENSATION SECURITIES ------------------------- UNDERLYING ALL OTHER NAME AND PRINCIPAL POSITION YEAR SALARY($) BONUS($) OPTIONS(#) COMPENSATION($)(4) - ----------------------------- ---- ------------- --------- --------------- ------------------ Sigi Ziering 1995 370,000 0 0 14,000 Chief Executive Officer 1994 340,000 0 0 14,000 1993 340,000 0 0 12,000 Michael Ziering 1995 175,000 0 20,000 18,000 President and Chief 1994 138,000 0 30,000 18,000 Operating Officer 1993 115,000 0 0 12,000 Said El Shami 1995 228,000 0 0 18,000 Senior Vice President -- 1994 210,000 0 0 20,000 Research and Development 1993 200,000 0 32,000(3) 20,000 Julian R. Bockserman 1995 152,000 0 0 18,000 Vice President -- Finance 1994 142,000 0 0 18,000 1993 132,000 0 16,000(3) 13,000 John G. McLaughlin 1995 150,000 24,000(2) 0 18,000 Vice President -- 1994 140,000 39,000(2) 0 18,000 Sales and Marketing 1993 125,000(1) 0 93,800(3) 14,000
- --------------- (1) Includes $14,000 for consulting services rendered prior to Mr. McLaughlin's employment by the Company in February 1993. (2) Represents amounts earned in accordance with a formula related to annual domestic sales performance. (3) 50,000 stock options were granted to Mr. McLaughlin as an incentive for his joining the Company in February 1993. These stock options were cancelled in November 1993 in exchange for 43,800 lower-priced stock options. All stock options granted to other Named Officers in 1993 were also granted in connection with the cancellation of a greater number of outstanding stock options. (4) The amounts in this column represent Company contributions to the Pension and/or Profit Sharing Plans in which all of the Company's employees are eligible to participate, except that the 1993 amount for Mr. McLaughlin represents moving costs and temporary living and transportation expenses in connection with his relocation to Los Angeles. 5 8 RETIREMENT AGREEMENT Upon his retirement, the Company has agreed to pay Dr. Ziering, or his surviving relatives, $3,000 per month for 120 months. Dr. Ziering has agreed not to compete with the Company while he receives such monthly payments, and he has also agreed to provide consulting services after his retirement. Discharge for cause will void the retirement payments to Dr. Ziering. 1995 STOCK OPTION GRANTS Shown below is information concerning stock option grants under the Company's 1990 Stock Option Plan during fiscal year 1995 to the Named Officers.
POTENTIAL REALIZABLE VALUE AT ASSUMED NUMBER OF RATES OF STOCK PRICE SECURITIES PERCENT OF APPRECIATION FOR UNDERLYING TOTAL OPTIONS EXERCISE OPTION TERM(2) OPTIONS GRANTED TO PRICE EXPIRATION --------------------- NAME GRANTED(#)(1) EMPLOYEES IN 1995 ($/SH) DATE 5%($) 10%($) - ----------------------- ------------- ----------------- ---------- ---------- -------- ---------- Sigi Ziering 0 0 0 0 0 0 Michael Ziering 20,000 13% 36.125 12/5/05 454,300 1,151,500 Said El Shami 0 0 0 0 0 0 Julian R. Bockserman 0 0 0 0 0 0 John G. McLaughlin 0 0 0 0 0 0
- --------------- (1) The stock options are exercisable beginning one year after the grant date at the rate of 10% per year and are subject to termination before the expiration date in the case of termination of employment, death and certain corporate events. Under the terms of the 1990 Stock Option Plan, the Stock Option Committee retains the discretion to modify the terms of outstanding stock options, including the exercise price and vesting schedule. (2) These amounts are net of the exercise price and are based on certain assumed rates of annual appreciation of the Common Stock during the term of the option. Actual gains, if any, are dependent on the future performance of the Common Stock and overall market conditions. The amounts reflected in this table may not necessarily be achieved, or may be exceeded. 6 9 1995 OPTION EXERCISES AND YEAR-END OPTION VALUES Shown below is information regarding options exercised during 1995 and holdings of unexercised stock options at December 31, 1995 by the Named Officers.
NUMBER OF SECURITIES UNDERLYING UNEXERCISED VALUE OF UNEXERCISED OPTIONS HELD AT DECEMBER IN-THE-MONEY OPTIONS AT SHARES 31, 1995(#) DECEMBER 31, 1995($)(1) ACQUIRED ON VALUE -------------------------- -------------------------- NAME EXERCISE(#) REALIZED($) EXERCISABLE UNEXERCISABLE EXERCISABLE UNEXERCISABLE - ----------------------- ------------- ------------- ----------- ------------- ----------- ------------- Sigi Ziering 500,000 15,206,250 0 0 0 0 Michael Ziering 4,800 133,800 19,200 52,000 426,450 541,500 Said El Shami 14,000 406,000 60,000 26,000 1,315,750 509,250 Julian R. Bockserman 0 0 23,000 13,000 495,125 254,625 John G. McLaughlin 0 0 8,760 35,040 156,585 626,340
- --------------- (1) Represents the difference between the aggregate market value on December 31, 1995 ($37.875 per share) and the aggregate exercise price. REPORT OF THE COMPENSATION AND STOCK OPTION COMMITTEES ON EXECUTIVE COMPENSATION The Company's executive compensation policies are administered by the Compensation Committee and the Stock Option Committee. The Compensation Committee reviews and determines the compensation of the Company's officers and evaluates management performance, management succession and related matters. The Compensation Committee's decisions are subject to ratification by the Board of Directors. The Stock Option Committee administers the Company's stock option plans and is responsible for decisions concerning stock option recipients and the timing, pricing and amount of stock options which are granted. The compensation policy of the Company is to provide competitive levels of compensation that are influenced by corporate performance, that reward individual achievements, and that enable the Company to attract and retain qualified executives. Compensation consists primarily of annual salary and long-term incentive compensation in the form of stock options. Bonuses are usually awarded only in extraordinary circumstances when, in the Compensation Committee's subjective judgment, the Company or a particular executive had exceptional performance during the prior year. Consistent with industry practices with respect to sales and marketing personnel, the Company has an arrangement with the Vice President-Sales and Marketing whereby such officer is paid an annual bonus based on domestic sales performance. The principal responsibility of the Compensation Committee is to determine the salary and bonus components of executive compensation, while the Stock Option Committee determines the stock option component. For 1995, the Compensation Committee recommended an 8.8% increase in the salary of Dr. Sigi Ziering, Chief Executive Officer, from $340,000 to $370,000. This increase was based on the Company's overall financial performance in 1994 and the Committee's subjective assessment of Dr. Ziering's performance over a three year period during which he successfully guided the Company through a transition from a reagent manufacturer to a fully integrated systems company. During this transition period, Dr. Ziering, at his request, did not receive any salary increases. 7 10 The 1995 salaries of the Company's other executive officers were principally based on Dr. Ziering's recommendations, which reflected his subjective assessment of the nature of each officer's position, contribution to the Company's overall performance, experience and tenure with the Company. The Committee evaluated such recommendations in light of the Company's overall financial performance in 1994, but the Company does not establish targets or financial performance standards. The Committee also compared the recommended salary increases with Company-wide employee compensation increases for 1995 and compensation surveys of companies in the health industry (including companies in the S&P Midcap Medical Products Index) with which the Company competes for executive talent. The President's salary was not increased for 1995 since he had received an increase effective October 1, 1994 upon his promotion to that office. The objective of the Stock Option Committee in granting stock options is to provide long-term incentives through the opportunity to participate in the long-term increase in the market value of the Common Stock. Stock options typically have a term of ten years and become exercisable after one year in cumulative installments which have ranged from 10% to 25% for executive officers. Stock options are not awarded annually, but are awarded in recognition of outstanding performance, based on the Committee's and management's subjective evaluations, and as an incentive to attract new executives. When the Stock Option Committee decides to grant options, it also takes into account the amount and value of outstanding options held by the executive. During 1995, Dr. Ziering exercised stock options for 500,000 shares with a net value realized (excess of market value on the date of exercise over the exercise price) of $15,206,250. The options had been granted in November 1985 at an exercise price of $7.50 per share, the market value on the date of grant. The net value realized by Dr. Ziering reflects the long term appreciation in the Company's stock price which, the Stock Option and Compensation Committees believe, was due, in large part, to Dr. Ziering's stewardship of the Company during such period. Section 162 of the Internal Revenue Code eliminates the deductibility of most compensation over $1 million per year paid to certain top executives of publicly-held corporations unless certain criteria are satisfied. The compensation realized by Dr. Ziering from the exercise of stock options in 1995 was exempt from the deductibility limit because the options were granted prior to the enactment of Section 162. The current level of executive compensation, including the value of exercisable options which are not exempt from the deductibility limits, does not exceed the deductibility limit. The Compensation Committee will, however, continue to evaluate whether compliance with the deductibility requirements of Section 162 is appropriate. The Company also maintains broad-based employee benefit plans in which executive officers participate on the same terms as other employees. For fiscal year 1995, the Company contributed 10% of participants' compensation to its Pension Plan and 2% of participants' compensation to the Profit Sharing Plan. Certain executive officers received reduced amounts due to limitations imposed by the Internal Revenue Code. The Compensation Committee The Stock Option Committee Louis Colen Maxwell H. Salter Maxwell H. Salter Marilyn Zierling 8 11 COMPENSATION AND STOCK OPTION COMMITTEE INTERLOCKS AND INSIDER PARTICIPATION During 1995, the members of the Compensation Committee were Joseph Kleiman and Maxwell H. Salter, both of whom were non-employee directors of the Company, and Louis Colen, a shareholder of the Company. Mr. Kleiman, who passed away in January 1996, received $24,000 for consulting services rendered to the Company during 1995. The members of the Stock Option Committee are Maxwell H. Salter, a non-employee director of the Company, and Marilyn Ziering, a director and Vice President -- Marketing Communications for the Company. Mrs. Ziering and Mr. Salter are "disinterested" persons for purposes of Rule 16b-3 under the Securities Exchange Act of 1934. Since 1981, the Company has leased its principal offices from a partnership comprised of Dr. Sigi Ziering, Marilyn Ziering and Michael Ziering, officers and directors of the Company, and other children of Sigi and Marilyn Ziering who are shareholders of the Company. In February 1991, the Company executed a new lease with the Ziering partnership for a term expiring on December 31, 1997, with a five-year renewal option. The monthly rent is subject to periodic cost of living adjustments. The terms of the lease were approved by a committee consisting of disinterested directors of the Company and a shareholder of the Company. During 1995, the Company paid $849,000 in rent to the Ziering partnership. 9 12 DPC STOCK PRICE PERFORMANCE Set forth below is a line graph which compares the cumulative total shareholder return, assuming dividend reinvestment, on the Company's Common Stock for the five years ended December 31, 1995, with the S&P Composite-500 Stock Index and the S&P Midcap Medical Products Index.
S&P Midcap Diagnostic Medical Measurement Period Products S&P 500 Products (Fiscal Year Covered) Corporation Index Index 1990 100 100 100 1991 110.60 130.47 216.97 1992 90.98 140.41 209.51 1993 57.80 154.56 168.92 1994 83.05 156.60 190.34 1995 121.38 215.45 270.10
The amounts in the foregoing table assume that the value of an investment in Diagnostic Products Corporation and each index was $100 on December 31, 1990. The annual amounts are based on monthly compounding with dividends reinvested. 10 13 OWNERSHIP OF COMMON STOCK The following table sets forth information as of March 15, 1996, with respect to Common Stock of the Company owned by each person who is known by the Company to own beneficially 5% or more of the outstanding Common Stock, by each director and Named Officer of the Company and by all directors and executive officers as a group.
NUMBER PERCENTAGE NAME* OF SHARES OWNERSHIP ------- --------- ---------- Sigi and Marilyn Ziering 2,486,806(1)(2) 18.4% 5700 West 96th Street Los Angeles, California 90045 Louis Colen 908,000 6.7% 2727 Krim Drive Los Angeles, California 90064 Maxwell H. Salter 345,600 2.6% Sidney A. Aroesty 107,400(2) ** Dr. James D. Watson 36,166(3) ** Michael Ziering 260,163(4) 1.9% Frederick Frank 0 -- Julian R. Bockserman 72,000(2)(5) ** Said El Shami 60,000(6) ** John G. McLaughlin 8,760(7) ** All directors and executive officers as a group (11 persons) 3,321,235(8) 24.3%
- ------------ * Includes addresses of 5% or more shareholders. ** Less than 1%. (1) Dr. and Mrs. Ziering, husband and wife, hold their shares in a revocable family trust of which they are co-trustees; excludes 19,150 shares owned by Dr. Ziering's mother who resides with Dr. and Mrs. Ziering and as to which beneficial ownership is disclaimed. (2) Includes 30,000 shares owned by the Company's Profit Sharing Plan over which Sigi Ziering, Sidney A. Aroesty and Julian R. Bockserman, as trustees, have shared voting and investment power. Beneficial ownership is disclaimed except as to each person's proportionate interest in such plan. These shares are counted once in the total number of shares held by all directors and executive officers as a group. (3) Includes 19,766 shares subject to options which are exercisable within 60 days. (4) Includes 19,200 shares subject to options which are exercisable within 60 days, and 1,000 shares held by Mr. Ziering's wife, as to which beneficial ownership is disclaimed. (5) Includes 23,000 shares subject to options which are exercisable within 60 days. (6) Includes 60,000 shares subject to options which are exercisable within 60 days. (7) Includes 8,760 shares subject to options which are exercisable within 60 days. (8) See Notes above. Also includes 4,340 shares subject to options which are exercisable within 60 days held by an executive officer not named in the foregoing table. 11 14 THE COMPANY'S AUDITORS It is the current intention of the Company's Board of Directors to select and retain Deloitte & Touche LLP as independent auditors of the Company for the current year. Deloitte & Touche LLP conducted the audit for the year ended December 31, 1995. A representative of Deloitte & Touche LLP will be present at the Meeting and will have an opportunity to make statements if he so desires and will be available to respond to appropriate questions. FORM 10-K A copy of the Company's Annual Report on Form 10-K for the year ended December 31, 1995 as filed with the Securities and Exchange Commission accompanies this Proxy Statement. SHAREHOLDER PROPOSALS FOR 1997 ANNUAL MEETING In order for a shareholder proposal to be included in the Board of Directors' Proxy Statement for the Annual Meeting of Shareholders to be held in 1997, such proposal must be received no later than the close of business on November 30, 1996, at 5700 West 96th Street, Los Angeles, California 90045, Attention: Corporate Secretary. OTHER MATTERS As of the date of this Proxy Statement, the Board of Directors does not know of any other matter which will be brought before the Annual Meeting. However, if any other matter properly comes before the Meeting, or any adjournment thereof, the person or persons voting the proxies have authority to vote on such matters in accordance with their judgment and discretion. By Order of the Board of Directors MARILYN ZIERING Secretary Los Angeles, California March 28, 1996 12 15 PROXY DIAGNOSTIC PRODUCTS CORPORATION PROXY FOR ANNUAL MEETING OF SHAREHOLDERS MAY 8, 1996 The undersigned hereby appoints DR. SIGI ZIERING and MICHAEL ZIERING, and each of them, the attorneys and proxies of the undersigned with full power of substitution to appear and to vote all of the common shares of DIAGNOSTIC PRODUCTS CORPORATION held of record by the undersigned on March 15, 1996, at the Annual Meeting of Shareholders of said Company to be held on May 8, 1996, or any adjournment thereof, as designated herein. (CONTINUED AND TO BE SIGNED ON THE OTHER SIDE) - ------------------------------------------------------------------------------- FOLD AND DETACH HERE 16 ____ Please mark your vote as X indicated in ____ this example FOR all WITHHOLD nominees listed AUTHORITY below (except to vote for all as marked to the nominees contrary below) listed below 1. ELECTION OF DIRECTORS ____ ____ (Instruction: To withhold authority to vote for any individual nominee, ____ ____ write that nominee's name on the space provided below.) Nominees: Dr. Sigi Ziering, Sidney A. Aroesty, Marilyn Ziering, Maxwell H. Salter, Dr. James D. Watson, Michael Ziering, Frederick Frank _____________________________________________ 2. IN THEIR DISCRETION, THE PROXIES ARE AUTHORIZED TO VOTE ON SUCH OTHER MATTERS AS MAY PROPERLY COME BEFORE THE MEETING OR ANY ADJOURNMENT THEREOF. THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS OF DIAGNOSTIC PRODUCTS CORPORATION. IF NO VOTE IS INDICATED, THIS PROXY WILL BE VOTED WITH AUTHORITY FOR THE ELECTION OF DIRECTORS. YOUR ARE URGED TO DATE, SIGN AND PROMPTLY RETURN THIS PROXY IN THE ENVELOPE PROVIDED. IT IS IMPORTANT FOR YOU TO BE REPRESENTED AT THE MEETING. THE EXECUTION OF YOUR PROXY WILL NOT AFFECT YOUR RIGHT TO VOTE IN PERSON IF YOU ARE PRESENT AT THE MEETING. Signature(s)__________________________________________ Date ___________________ IMPORTANT: Please sign as name appears herein. When signing as an attorney, executor, administrator, trustee or guardian, give full title as such. If the signatory is a corporation, sign the full corporate name by duly authorized officer, or if a partnership, sign in partnership name by authorized person. Joint owners should each sign. - -------------------------------------------------------------------------------- FOLD AND DETACH HERE -----END PRIVACY-ENHANCED MESSAGE-----